FM-VP4 Forbes Medi-Tech.
Copyright policy )FM-VP4 Forbes Medi-Tech.
FM-VP4 is a phytosterol analog under development by Forbes Medi-Tech for the potential treatment of hyperlipidemia and hypercholesterolemia. By March 2002, FM-VP4 had entered phase I clinical trials and phase II trials were underway by late 2002.
- University of Western Australia Australia
- Royal Perth Hospital Australia
Clinical Trials, Phase I as Topic, Molecular Structure, Hypercholesterolemia, Phytosterols, Hyperlipidemias, Cholesterol, LDL, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Humans, Hypolipidemic Agents, Randomized Controlled Trials as Topic
Clinical Trials, Phase I as Topic, Molecular Structure, Hypercholesterolemia, Phytosterols, Hyperlipidemias, Cholesterol, LDL, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Humans, Hypolipidemic Agents, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!